{"entity":{"id":"primelink-biotherapeutics","kind":"company","name":"PrimeLink BioTherapeutics","aka":["Primelink BioTherapeutics (ShenZhen) Limited","普灵生物医药（苏州）有限公司"],"tldr":"PrimeLink BioTherapeutics makes antibody-drug conjugates, including ones that carry two different cancer-killing drugs; its first, PLB-002, is in an early trial in advanced solid tumours.","summary":"PrimeLink BioTherapeutics (普灵生物医药), based in Suzhou Industrial Park with a Shenzhen entity as the registry sponsor, develops antibody-drug conjugates on a modular conjugation platform it calls ENHANMIX, including dual-payload ADCs, degrader-antibody conjugates and bispecific ADCs. Its pipeline lists PLB-002, a monoclonal antibody ADC for ovarian and lung cancer, in a phase 1 study in advanced solid tumours (NCT07304128), with PLB-001, PLB-003, PLB-004 and PLB-005 earlier in development. Its first registered cancer trial, NCT07304128, was posted on ClinicalTrials.gov in December 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.primelinkbio.com/"},{"label":"Pipeline","url":"https://www.primelinkbio.com/pipeline/1.html"},{"label":"ClinicalTrials.gov: phase 1 trial of PLB-002 (NCT07304128)","url":"https://clinicaltrials.gov/study/NCT07304128"}],"tags":[],"related":[],"cancers":["ovarian","lung-cancer"],"sections":["adcs"],"technologies":["adc","dual-payload-adc","bispecific-adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website (Chinese) and pipeline page read on 29 October 2026. The target of PLB-002 is not disclosed on the pages read. Founding year not stated. No financing amounts read."],"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.primelinkbio.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/primelink-biotherapeutics/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/"}]}}